CSTONE PHARMA-B News

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2025

May 8 05:14 ET

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE PRESENTED FIVE LATEST STUDIES AT 2025 AACR ANNUAL MEETING

May 5 20:00 ET

CSTONE PHARMA-B: ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024

Apr 28 08:07 ET

CSTONE PHARMA-B: 2024 ANNUAL REPORT

Apr 28 08:05 ET

CSTONE PHARMA-B: (I) GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSUSCHEME; AND(II) GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP

Apr 11 07:25 ET

CSTONE PHARMA-B: NEXT DAY DISCLOSURE RETURN

Apr 10 07:29 ET

CSTONE PHARMA-B: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Apr 10 07:23 ET

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 560,000 SHARES, WITH ACCUMULATED PURCHASE TOTALLING 10,359,000 SHARES

Apr 9 00:28 ET

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2025

Apr 7 04:44 ET

CSTONE PHARMA-B: PLACING OF NEW SHARES UNDER GENERAL MANDATE

Apr 1 20:00 ET

CSTONE PHARMA-B: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DECEMBER 31, 2024

Mar 27 04:30 ET

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE TO SHOWCASE FIVE LATEST RESEARCH ACHIEVEMENTS AT AACR 2025

Mar 25 20:00 ET

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE SUBMITS APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR NEW INDICATION OF SUGEMALIMAB IN STAGE III NON-SMALL CELL LUNG CANCER

Mar 23 20:00 ET

CSTONE PHARMA-B: DATE OF BOARD MEETING

Mar 17 00:00 ET

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2025

Mar 6 03:31 ET

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES SUBMISSION OF CLINICAL TRIAL APPLICATION IN AUSTRALIA FOR CS5001 (ROR1 ADC) IN COMBINATION WITH FIRST-LINE STANDARD-OF-CARE FOR DLBCL

Mar 5 19:00 ET

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES FIRST PATIENT DOSED IN GLOBAL MULTICENTER PHASE I CLINICAL TRIAL OF CS2009, A PD-1/VEGF/CTLA-4 TRISPECIFIC ANTIBODY

Mar 3 19:00 ET

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES PUBLICATION OF GEMSTONE-303 STUDY RESULTS FOR SUGEMALIMAB (CEJEMLY) IN JAMA

Feb 24 23:00 ET

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES INCLUSION OF SUGEMALIMAB (CEJEMLY) AS FIRST-LINE COMBINATION THERAPY FOR NSCLC IN ESMO GUIDELINE

Feb 9 23:00 ET

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2025

Feb 6 04:27 ET